Research programme: antibacterial antibodies - Sorrento Therapeutics

Drug Profile

Research programme: antibacterial antibodies - Sorrento Therapeutics

Alternative Names: Anti-AIP mAbs; Anti-API1 mAb; Anti-API2 mAbs; Anti-MRSA antibodies - Sorrento Therapeutics; STI 001 program - Sorrento; STI-C0205; STI-C020X

Latest Information Update: 28 Aug 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Sorrento Therapeutics
  • Developer Montana State University; Ohio State University; Sorrento Therapeutics
  • Class Antibodies; Bispecific antibodies; Monoclonal antibodies; Vaccines
  • Mechanism of Action Immunostimulants; Peptide inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Methicillin-resistant Staphylococcus aureus infections; Pseudomonal infections
  • Discontinued Clostridium-difficile-infections

Most Recent Events

  • 28 Aug 2018 No recent reports of development identified for preclinical development in Pseudomonal-infections in USA (Parenteral)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in USA (Parenteral)
  • 29 Jan 2018 Discontinued for Clostridium difficile infections in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top